Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws

被引:44
作者
Klingelhoeffer, Christoph [1 ]
Zeman, Florian [2 ]
Meier, Johannes [1 ]
Reichert, Torsten Eugen [1 ]
Ettl, Tobias [1 ]
机构
[1] Hosp Univ Regensburg, Dept Cranio & Maxillofacial Surg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany
[2] Hosp Univ Regensburg, Dept Clin Studies, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany
关键词
Bisphosphonates; Denosumab; Osteonecrosis; Surgery; Recurrence; BISPHOSPHONATE-RELATED OSTEONECROSIS; ZOLEDRONIC ACID; CANCER-PATIENTS; BONE METASTASES; BREAST-CANCER; MANAGEMENT; DENOSUMAB; PREVALENCE; RESECTION; SHOWS;
D O I
10.1016/j.jcms.2016.08.001
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Purpose: Surgical treatment of the medication-related osteonecrosis of the jaw (MRONJ) is still challenging. We examined the outcome of the resection of osteonecrotic lesions and the influence of potential risk factors on the operative success. Methods: Seventy six surgical interventions on 40 patients were evaluated in a prospective design with a mean follow-up of 55 weeks. Primary endpoints were: (i) maintenance of the mucosal closure and (ii) decrease of MRONJ stage. Influential variables included preoperative duration, location and diameter of MRONJ, duration and change of antiresorptive therapy, presence of actinomyces species. Results: Only in 27.6% of cases long-term maintenance of the mucosal closure was achieved. However, stage II patients decreased to stage I in 81% after surgery (p < 0.01) and stage III patients improved in 83% of cases (OR = 8.08; p = 0.07). Stage I patients profited only in 38% by surgical intervention. MRONJ recurrence after surgery was associated with extended preoperative MRONJ duration (p = 0.015). There was no significance of further influential variables, but MRONJ of the upper jaw seems prognostically more favorable. Conclusion: Advanced stages of MRONJ benefit from surgical treatment, whereas stage I diseases may also be treated conservatively. An early intervention reduces the risk of recurrence. (C) 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1694 / 1699
页数:6
相关论文
共 50 条
  • [31] Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)
    Otto, Sven
    Aljohani, Suad
    Fliefel, Riham
    Ecke, Sara
    Ristow, Oliver
    Burian, Egon
    Troeltzsch, Matthias
    Pautke, Christoph
    Ehrenfeld, Michael
    MEDICINA-LITHUANIA, 2021, 57 (05):
  • [32] Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?
    Shimamoto, Hiroaki
    Grogan, Tristan R.
    Tsujimoto, Tomomi
    Kakimoto, Naoya
    Murakami, Shumei
    Elashoff, David
    Aghaloo, Tara L.
    Tetradis, Sotirios
    DENTOMAXILLOFACIAL RADIOLOGY, 2018, 47 (03)
  • [33] Quality of life in patients affected by medication-related osteonecrosis of the jaws: A systematic review
    Bensi, Caterina
    Giovacchini, Francesco
    Lomurno, Giuseppe
    Eramo, Stefano
    Barraco, Giancarlo
    Tullio, Antonio
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2021, 132 (02): : 182 - 189
  • [34] Outcomes of a Pharmacological Protocol with Pentoxifylline and Tocopherol for the Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Randomized Study on 202 Osteoporosis Patients
    Colapinto, Gianluca
    Goker, Funda
    Nocini, Riccardo
    Albanese, Massimo
    Nocini, Pier Francesco
    Sembronio, Salvatore
    Argenta, Francesca
    Robiony, Massimo
    Del Fabbro, Massimo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (14)
  • [35] Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies
    AlRowis, Raed
    Aldawood, Abdulmalik
    AlOtaibi, Mohammed
    Alnasser, Essam
    AlSaif, Ibrahim
    Aljaber, Abdullah
    Natto, Zuhair
    SAUDI DENTAL JOURNAL, 2022, 34 (03) : 202 - 210
  • [36] Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer
    Ueda, Nobuhiro
    Aoki, Kumiko
    Shimotsuji, Hiroko
    Nakashima, Chie
    Kawakami, Mao
    Imai, Yuichiro
    Kirita, Tadaaki
    JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (04) : 623 - 630
  • [37] Infection and Medication-related Osteonecrosis of the Jaw
    Katsarelis, H.
    Shah, N. P.
    Dhariwal, D. K.
    Pazianas, M.
    JOURNAL OF DENTAL RESEARCH, 2015, 94 (04) : 534 - 539
  • [38] Medication-related Osteonecrosis of the Jaw: A Review
    AlDhalaan, Nouf A.
    BaQais, Asma
    Al-Omar, Ahmad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (02)
  • [39] The first quantitative histomorphological analyses of bone vitality and inflammation in surgical specimens of patients with medication-related osteonecrosis of the jaw
    Mamilos, Andreas
    Spoerl, Steffen
    Spanier, Gerrit
    Ettl, Tobias
    Brochhausen, Christoph
    Klingelhoeffer, Christoph
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2021, 50 (01) : 76 - 84
  • [40] Role of Periapical Diseases in Medication-Related Osteonecrosis of the Jaws
    Rao, Nian Jing
    Wang, Jing Yi
    Yu, Ru Qing
    Leung, Yiu Yan
    Zheng, Li Wu
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017